All Outputs (2)

Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity (2017)
Journal Article
Donnellan, S., Stone, V., Johnston, H., Giardiello, M., Owen, A., Rannard, S., Aljayyoussi, G., Swift, B., Tran, L., Watkins, C., & Stevenson, K. (2017). Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity. Journal of Interdisciplinary Nanomedicine, 2(3), 146-156. https://doi.org/10.1002/jin2.27

Tuberculosis kills more people worldwide than any other infectious disease. Treatment requires multiple drug therapy administered over long periods (6–24 months). The emergence of multidrug‐resistant strains is a major problem, and with few new drugs... Read More about Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity.

Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration (2017)
Journal Article
Aljayyoussi, G., Jenkins, V. A., Sharma, R., Ardrey, A., Donnellan, S., Ward, S. A., & Biagini, G. A. (2017). Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Scientific Reports, 7(1), Article 502 (2017). https://doi.org/10.1038/s41598-017-00529-6

Tuberculosis (TB) treatment is long and complex, typically involving a combination of drugs taken for 6 months. Improved drug regimens to shorten and simplify treatment are urgently required, however a major challenge to TB drug development is the la... Read More about Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.